

Balaxi Pharmaceuticals Limited

May 30, 2024

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Newspaper Advertisement – Disclosure under Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement published today i.e., May 30, 2024, regarding the financial results of the Company for the quarter and year ended March 31, 2024, as published in Business Standard (English) and Nava Telangana (Telugu) newspapers.

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For Balaxi Pharmaceuticals Limited

Mahesh Inani
(Company Secretary and Compliance Officer)
Membership No.: A37577

Encl: A/a

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Note:

- a. The above is an extract of the detailed format of Audited Financial Results for the Year ended March 31, 2024, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the year ended March 31, 2024 is available on the websites of the Stock Exchange(s) and the company's website:- www.aspiradiagnostics.com.
- b. The above result has been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on May 28, 2024.

For and on behalf of the Board
For Aspira Pathlab & Diagnostics Limited
Sd/-

Nikunj V. Mange
Executive Director
DIN: 08489442

Place:- Mumbai
Date:- May 28, 2024

Balaxi Pharmaceuticals Limited

Registered Office: 2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2024

(Rs. in Lakhs, unless specified)

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter ended 31/03/2024	Year ended 31/03/2024	Quarter ended 31/03/2023	Year ended 31/03/2023	Quarter ended 31/03/2024	Year ended 31/03/2024	Quarter ended 31/03/2023	Year ended 31/03/2023
		Audited	Audited	Audited	Audited	Audited	Audited	Audited	Audited
1	Total Income from Operations	1,590.45	7,019.60	3,035.14	10,813.76	5,983.31	24,129.44	8,068.15	33,643.26
2	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	(26.42)	558.31	508.73	2,245.05	1,040.43	4,030.88	1,106.83	5,692.23
3	Net profit/(loss) for the period before tax (after exceptional and/or extraordinary items)	(26.42)	558.31	508.73	2,245.05	1,149.36	201.54	1,106.83	5,692.23
4	Net profit/(loss) for the period after tax (after exceptional and/or extraordinary items)	(57.52)	365.03	394.31	1,622.21	1,093.38	(238.69)	810.03	4,596.25
5	Total Comprehensive Income for the period (Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax))	(57.52)	365.03	394.31	1,622.21	1,061.34	(780.58)	791.55	5,174.44
6	Paid-up Equity Share Capital [Face value of Rs. 10 each]	1,089.77	1,089.77	1,018.13	1,018.13	1,089.77	1,089.77	1,018.13	1,018.13
7	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year		11,064.91		8,192.53		19,046.56		17,269.85
8	Earnings Per Share (of Rs.10/- each)	(0.55)	3.55	3.90	16.17	10.41	(2.32)	8.01	45.81
	1. Basic (amount in Rs.)								
	2. Diluted (amount in Rs.)	(0.55)	3.54	3.83	16.02	10.38	(2.31)	7.86	45.40

Notes:

a) The above is an extract of the detailed format of Financial Results for the quarter and year ended March 31, 2024 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Audited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.

b) The above Audited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 29, 2024 respectively. The said Financial Results are prepared in accordance with the Indian Accounting Standards, (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of Board of Directors,
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Place: Hyderabad
Date: May 29, 2024

